Table 3.
Ongoing clinical trials investigating novel targeting agents.
| PARP inhibitors | Eligibility based on targeted genetic mutation | Combination | Study phase | Treatment setting | Sponsor | Clinicaltrials.gov identifier | Estimated study completion time |
|---|---|---|---|---|---|---|---|
| Olaparib | Germline BRCA1/2 | None | II | Any | AstraZeneca | NCT01078662 | 31 December 2021 |
| Genetic aberrations associated with HRD,* must be germline BRCA1/2 negative | None | II | Second line | AstraZeneca | NCT02677038 | 30 November 2022 | |
| No specific genetic targets | Cediranib (VEGF inhibitor) | II | Second line | National Cancer Institute | NCT02498613 | 31 December 2021 | |
| Germline BRCA1/2 | Pembrolizumab | II | Second line | National Cancer Institute | NCT04548752 | 31 March 2025 | |
| No specific genetic targets | None (cobimetinib as parallel arm) | I | Any | OHSU Knight Cancer Institute | NCT04005690 | 1 February 2025 | |
| No specific genetic targets, ARID1A/ATM loss subgroup | AZD6738 (ATR kinase inhibitor) | II | Second line or more | AstraZeneca | NCT03682289 | 19 March 2023 | |
| No specific genetic targets | AZD5153 (BET/BRD4 bromodomain inhibitor) | I | Second line or more | AstraZeneca | NCT03205176 | 30 March 2021 | |
| No specific genetic targets | Multi-agents low dose chemotherapy followed by maintenance pembrolizumab | II | First line | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCT04753879 | April 2025 | |
| Rucaparib | Germline or somatic BRCA1/2 or PALB2 | None | II | Maintenance | Abramson Cancer Center, UPenn | NCT03140670 | 1 June 2022 |
| No specific genetic targets | Liposomal irinotecan, 5-fluorouracil and leucovorin | I/II | Any | Academic and Community Cancer Research United | NCT03337087 | 1 July 2022 | |
| Germline or somatic BRCA 1/2, PALB2, RAD51C, RAD51D, BARD1, FANCA, NBN, RAD51, or RAD51B | None | II | Second line or more | Clovis Oncology, Inc. | NCT04171700 | May 2022 | |
| Niraparib | No specific genetic targets | Ipilimumab or nivolumab | I/II | Second line | Upenn | NCT03404960 | December 2021 |
| No specific genetic targets | None | II | Any | University of Kansas Medical Center | NCT03553004 | 1 February 2025 | |
| Germline or somatic BRCA1/2, PALB2, CHEK2 or ATM | None | II | Second line or more | Dana-Farber Cancer Institute | NCT03601923 | 28 February 2025 | |
| No specific genetic targets | Dostarlimab plus radiation | II | Any | Massachusetts General Hospital | NCT04409002 | 1 October 2026 | |
| Germline or somatic BRCA1/2, PALB2, BARD1, RAD51c, RAD51d | Dostarlimab | II | Second and third line | Mayo Clinic | NCT04493060 | 1 December 2022 | |
| Germline or somatic BRCA1/2, ATM, ATR, BAP1, BRIP1, CHEK2, FANCA, PALB2, RAD51 | Anlotinib | I | Second line | Beijing Cancer Hospital | NCT04764084 | 28 February 2023 | |
| Germline or somatic BRCA1/2 | TSR-042 | Ib | Second line or more | University of Washington | NCT04673448 | 30 March 2026 | |
| Talazoparib | Genes involved in DDR,** deleterious mutations confer sensitivity to PARP inhibitors (germline or somatic)+ | None | II | Any | National Cancer Institute | NCT04550494 | 1 December 2023 |
| Veliparib | No specific genetic targets | FOLFIRI or mFOLFIRI | II | Second line | National Cancer Institute | NCT02890355 | 1 May 2019 (completed) |
| Personal or family history of mutation in BRCA1/2, PALBB2, or one of the FANC genes | mFOLFOX6 | I/II | Any | Georgetown University | NCT01489865 | 31 December 2020 | |
| Germline or somatic BRCA1/2 or PALB2 | Cisplatin and gemcitabine | II | Any | National Cancer Institute | NCT01585805 | 1 December 2021 | |
| No specific genetic targets | Irinotecan hydrochloride | I | Any | National Cancer Institute | NCT00576654 | 30 June 2021 |
*
Homologous recombination deficiency.
**
DNA damage response.
+
Deleterious BRCA1 or BRCA2 mutations, loss of function mutations in FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM, FANCN. A known functional mutation in ATM, BACH1 (BRIP1), BARD1, CDK12, CHK1, CHK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L.
Last accessed date of clinicaltrials.gov: 8 March 2021.